RECOMBINANT HUMANISED IgG1 KAPPA ANTI-CLDN1 MONOCLONAL ANTIBODY ALE.F02
Advanced Liver Fibrosis
Alentis Therapeutics AGmonoclonal_antibodyPhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
26 Active assets in the Advanced Liver Fibrosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Entecavir Tanta University | Phase 4 | BB |
Peg-Intron Beth Israel Deaconess Medical Center | Phase 4 | BB |
COLCHICINUM Zagazig University | Phase 4 | BB |
Peg-Ifn Beijing Friendship Hospital | Phase 4 | BB |
Hydronidone Beijing Continent Pharmaceutical Co, Ltd. | Phase 3 | BB |
View all 50 →
Same molecule, other indications
RECOMBINANT HUMANISED IgG1 KAPPA ANTI-CLDN1 MONOCLONAL ANTIBODY ALE.F02 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →